Oral agents in type 2 diabetes: where to now?

被引：2

作者：

Campbell, LV ^{[1
]}

Chisholm, DJ

机构：

[1] St Vincents Hosp, Ctr Diabet, Sydney, NSW 2010, Australia

[2] St Vincents Hosp, Garvan Inst Med Res, Diabet & Metab Program, Sydney, NSW 2010, Australia

来源：

MEDICAL JOURNAL OF AUSTRALIA | 1999年 / 171卷 / 02期

关键词：

D O I：

10.5694/j.1326-5377.1999.tb123520.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：64 / 65

页数：2

共 10 条

[1]

Buse JB, 1999, DIABETES CARE, V22, pC65

[2] Pathogenesis of the insulin resistance syndrome (Syndrome X) [J].

Chisholm, DJ ;

Campbell, LV ;

Kraegen, EW .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1997, 24 (9-10) :782-784

[3]

Draznin B, 1998, DIABETES, V47, pA85

[4] A novel antidiabetic drug, troglitazone - Reason for hope and concern [J].

Imura, H .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :908-909

[5] Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus [J].

Inzucchi, SE ;

Maggs, DG ;

Spollett, GR ;

Page, SL ;

Rife, FS ;

Walton, V ;

Shulman, GI .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :867-872

[6] Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes [J].

Kelly, IE ;

Han, TS ;

Walsh, K ;

Lean, MEJ .

DIABETES CARE, 1999, 22 (02) :288-293

[7] Alpha-glucosidase inhibitors [J].

Lebovitz, HE .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1997, 26 (03) :539-&

[8] Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes [J].

Moses, R ;

Slobodniuk, R ;

Boyages, S ;

Colagiuri, S ;

Kidson, W ;

Carter, J ;

Donnelly, T ;

Moffitt, F ;

Hopkins, H .

DIABETES CARE, 1999, 22 (01) :119-124

[9] Hepatic dysfunction associated with troglitazone [J].

Watkins, PB ;

Whitcomb, RW .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :916-917

[10]

Watkins PJ, 1998, DIABETIC MED, V15, P895

← 1 →